Author’s response to reviews

Title: Evaluation of microvascular changes in the perifoveal vascular network using Optical Coherence Tomography Angiography (OCTA) in type I Diabetes Mellitus: A large scale prospective trial

Authors:

Javier Zarranz-Ventura (jzarranz@hotmail.com)
Marina Barraso (marinabarraso@gmail.com)
Anibal Alé-Chilet (anibalale@gmail.com)
Teresa Hernandez (tessa.hrndz@gmail.com)
Cristian Oliva (cristianolpa10@gmail.com)
Jesus Gascón (jesusgascon.1987@gmail.com)
Anna Sala-Puigdollers (annasalapuigdollers@hotmail.com)
Marc Figueras-Roca (m.figuерas.roca@gmail.com)
Irene Vinagre (ivinagre@clinic.cat)
Emilio Ortega (eortega1@clinic.cat)
Enric Esmatjes (esmatjes@clinic.cat)
Alfredo Adan (amadan@clinic.cat)

Version: 1 Date: 11 Sep 2019

Author’s response to reviews:

11th September 2019

Response to Editor – Minor revision
BMC Medical Imaging journal
Manuscript number: BMIM-D-19-00204

We appreciate the comments of the editor - we are pleased to submit a revised manuscript addressing the point that has been raised. We believe the editor's recommendation have allowed us to further improve the quality of our paper.
Editor Comments:

1. Please add a power calculation for the sample size.

Response: We thank the editor for his suggestion to add a clarification of the estimation of the sample size. We have amended the manuscript accordingly and we have included a specific section entitled “Sample size” after the “Study population” section to explain concisely why we selected a target population of 1000 patients. Given that no normative databases are available for vessel density in normal eyes the project was designed in an exploratory basis. Therefore, the sample size was estimated from the total number of type 1 DM patients seen yearly in the Diabetes Unit of Hospital Clínic (n = 2000 type 1 DM patients). All of them will be offered to enter the study voluntarily, and based on previous studies carried out in the DM unit in other DM complications (i.e. in diabetic chronic kidney disease) we anticipated an estimated opt-out rate of 50%. For this reason, we set a target sample size of 1000 patients (50% of 2000 patients).

We do believe that this clarification has strengthened the paper, and we do hope that with the amendments done the manuscript is now suitable for publication.

Yours sincerely,

Javier Zarranz-Ventura MD PhD FEBO

Corresponding author

Phone: +34 660008417
jzarranz@hotmail.com